Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 523Leukemia, Myeloid, Acute 499Neoplasms 381Carcinoma, Non-Small-Cell Lung 381Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 319Multiple Myeloma 312Glioblastoma 311Melanoma 310Prostatic Neoplasms 293Leukemia 289Neoplasm Metastasis 284Brain Neoplasms 277Lymphoma 271Lung Neoplasms 270Recurrence 267Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Glioma 209Myelodysplastic Syndromes 208Lymphoma, Large B-Cell, Diffuse 186Carcinoma, Hepatocellular 173Lymphoma, Follicular 167Head and Neck Neoplasms 162Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Thyroid cancer, Hurthle cell × Clear all
NCT05410821 2025-04-01

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

The First Affiliated Hospital of Xiamen University

Phase 1 Completed
12 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡